Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema

BioDrugs

Volumn 21, Issue 4, 2007, Pages 245-257

  Emerson, M Vaughn ^a   Lauer, Andreas K ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b CASEY EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ADENOVIRUS VECTOR; ANACORTAVE ACETATE; ANECORTAVE; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; BEVASIRANIB; CORTICOSTEROID; DEXAMETHASONE; EVIZON; FLUOCINOLONE ACETONIDE; ION CHANNEL; OCTREOTIDE; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; PLACEBO; PROTEIN KINASE C; RANIBIZUMAB; RUBOXISTAURIN; SMALL INTERFERING RNA; SQUALAMINE; SQUALAMINE LACTATE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VATALANIB;

ARGON PLASMA COAGULATION; ARTERIAL THROMBOEMBOLISM; CELL MEMBRANE; CEREBROVASCULAR ACCIDENT; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG EFFECT; DRUG IMPLANT; ENDOPHTHALMITIS; ENZYME ACTIVITY; FATIGUE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; LASER COAGULATION; MONOTHERAPY; NAUSEA AND VOMITING; NONHUMAN; PERFORMANCE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN BINDING; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; STROKE; SUBRETINAL NEOVASCULARIZATION; THROMBOEMBOLISM; UVEITIS; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOLESTANOLS; CHOROIDAL NEOVASCULARIZATION; DIABETIC RETINOPATHY; DRUG THERAPY, COMBINATION; HUMANS; INDOLES; LACTATES; LASER COAGULATION; MACULAR DEGENERATION; MACULAR EDEMA, CYSTOID; MALEIMIDES; OCTREOTIDE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PREGNADIENEDIOLS; PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTORS; VITRECTOMY;

EID: 34547119296     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200721040-00005     Document Type: Review

References (100)

1. World Health Organization. Magnitude and causes of visual impairment [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs282/ en/index.html [Accessed 2006 Dec 19]
2. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122: 564-72
3. Klein R, Klein BEK, Knudtson MD, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the Multi-Ethnic Study of Atherosclerosis. Arch Ophthalmol 2006; 113: 373-80
4. Eye Diseases Prevalence Research Group. Prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122: 552-63
5. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: 3-year results from randomized clinical trials. Arch Ophthalmol 1986; 104: 694-701
6. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP report 2. Arch Ophthalmol 2001; 119: 198-207
7. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change from baseline with and without verteporfin therapy in choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003; 136: 407-18
8. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 1805-16
9. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31
10. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44
11. Schmidt-Erfurth U. How often is re-treatment with Lucentis® needed? [abstract]. American Academy of Ophthalmology Annual Meeting: Subspecialty Day - Retina; 2006 Nov 11-14; Las Vegas (NV)
12. Rosenfeld PJ, Puliafito CA, Fung AE, et al. OCT-guided variable-dosing regimen with Lucentis® (ranibizumab) in neovascular AMD: one year results from the PrONTO study. American Society of Retina Specialists/European Vitreoretinal Society Annual Meeting; 2006 Jul 9-13 [abstract no. 508; online]. Available from URL: http://www.evrs.org/pages/2006/ Scientifis%20Sessions_abstracts/Sunday/508.pdf [Accessed 2007 May 18]
13. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-90
14. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin®) for neovascular age-related macular degeneration. Retina 2006; 26: 495-511
15. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin®) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72
16. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142: 141-3
17. Nguyen QD, Hariprasad S, Shah SM, et al. Results of a phase I, dose-escalation, safety, tolerability, and bioactivity study of intravitreal VEGF trap in patients with neovascular age-related macular degeneration: the CLEAR-IT 1 study [abstract]. Retina Society/Club Jules Gonin Annual Meeting; 2006 Oct 15-20; Cape Town
18. Brucker AJ. Small interfering RNA (Cand 5) for the treatment of subfoveal choroidal neovascularization due to age-related macular degeneration [abstract]. Retina Society/Club Jules Gonin Annual Meeting; 2006 Oct 15-20; Cape Town
19. Shen J, Samul R, Akiyama H, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006; 13: 225-34
20. Joondeph BC. ADVANCE: study of vatalanib in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration [abstract]. Retina Society/Club Jules Gonin Annual Meeting; 2006 Oct 15-20; Cape Town
21. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006; 17: 67-176
22. Kaiser PK. Other treatments for neovascular AMD: VEGF trap, squalamine, and tyrosine kinase inhibitors [abstract]. American Academy of Ophthalmology Annual Meeting: Subspecialty Day - Retina; 2006 Nov 11-14; Las Vegas (NV)
23. Slakter JS, Bochow T, D'Amico DJ, et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006; 113: 3-13
24. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: ETDRS report no. 1. Arch Ophthalmol 1985; 103: 1796-806
25. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920-7
26. Jonas JB, Kreissing I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 2003; 121: 57-61
27. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006; 113: 11533-8
28. Friedman SM. Results of peribulbar steroids for diabetic macular edema [abstract]. American Academy of Ophthalmology Annual Meeting: Subspecialty Day - Retina; 2006 Nov 11-14; Las Vegas (NV)
29. Ip MS, Comstock T. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multi-center clinical trial [abstract]. Retina Society/Club Jules Gonin Annual Meeting; 2006 Oct 15-20; Cape Town
30. The Macugen® Diabetic Retinopathy Study Group. A phase II randomized, double-masked, trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-57
31. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005
32. Arevalo JF, Fromow-Guerra J, Quiroz-Mercardo H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Pan-American Collaborative Retina Study Group. Ophthalmol 2007; 114: 743-50
33. Shah SM, Nguyen QD, Tatlipinar S, et al. One-year results of the READ study: ranibizumab for edema of the macula in diabetes [abstract]. Retina Society/Club Jules Gonin Annual Meeting; 2006 Oct 15-20; Cape Town
34. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113: 1522-32
35. The PKC-DRS Study Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006 Dec; 113 (12): 2221-30
36. Green WR, Enger C. Age-related macular degeneration histopathologic studies: the 1992 Lorenz E Zimmerman Lecture. Ophthalmology 1993; 100: 1519-35
37. Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Survey Ophthalmol 2003; 48: 257-93
38. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol 1993; 111: 1200-9
39. Macular Photocoagulation Study Group. Laser photocoagulation of juxtafoveal choroidal neovascularization: 5-year results from randomized clinical trials. Arch Ophthalmol 1994; 111: 500-9
40. Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1982; 100: 912-8
41. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1991; 109: 1220-31
42. Schmidt-Erfurth U, Scholtzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44: 4473-80
43. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611
44. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005; 25: 111-8
45. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 3186-93
46. Keyt BA, Berleau LT, Nguyen HV, et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996; 271: 7788-95
47. Adamis AP, Drilleke D, Nishijima K, et al. The role of VEGF in inflammation and neuroprotection [abstract]. American Academy of Ophthalmology Annual Meeting: Subspecialty Day - Retina; 2006 Nov 11-14; Las Vegas (NV)
48. Ferrara N, Hillan KJ, Gerer HP, et al. Discovery and development of bevacizumab, and anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400
49. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999; 293: 865-81
50. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-9
51. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multtidose study. Ophthalmology 2006; 113: 633-42
52. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42
53. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin®) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006; 113: 2002-11
54. Ferris FL, Kassoff A, Bresnick GH, et al. New visual acuity charts for clinical research. Am J Ophthalmol 1982; 94: 91-6
55. Fung AE, Rosenfeld PJ, Reichel EZ. The International Intravitreal Avastin® Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-9
56. Bakri SJ, Snyder MR, Pulido JS, et al. Six-month stability of bevacizumab (Avastin®) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 2006; 26: 519-22
57. Maier P, Unsoeld AS, Junker B, et al. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischaemia-induced retinopathy in a rat. Graefes Arch Clin Exp Ophthalmol 2005; 243: 593-600
58. Steele FR, Chader GJ, Johnson LV, et al. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci U S A 1993; 90: 1526-30
59. Mori K, Gehlbach P, Ando A, et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002; 43: 2428-34
60. Carríon ME, Hamilton MM, Harris B, et al. Ocular pharmacokinetics of pigment epithelium-derived factor (PEDF) following adenovector-based gene delivery indicate that low levels of PEDF are therapeutic. Association for Research in Vision and Ophthalmology Annual Meeting; 2005 May 1-5; Fort Lauderdale (FL). Invest Ophthalmol Vis Sci 2005; 46: E-abstract no. 5211
61. Hamilton MM, Brough DE, McVey D, et al. Repeated administration of adenovector in the eye results in efficient gene delivery. Invest Ophthalmol Vis Sci 2006; 47: 299-305
62. Ciulla TA, Criswell MH, Danis RP, et al. Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina 2003; 23: 808-14
63. Slakter JS, Anecortave Acetate Clinical Study Group. Retaane update. American Academy of Ophthalmology Annual Meeting: Subspecialty Day - Retina; 2006 Nov 11-14; Las Vegas (NV).
64. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol 2006; 124: 1532-42
65. Lanzetta P. Intravitreal ranibizumab plus verteporfin photodynamic therapy for neovascular age-related macular degeneration: year 2 FOCUS results [abstract]. Retina Society/Club Jules Gonin Annual Meeting; 2006 Oct 15-20; Cape Town
66. Agustin AJ, Offermann I. Photodynamic therapy and steroids: initial combination therapy leading to the study of triple therapy with verteporfin PDT, bevacizumab, and dexamethasone [abstract]. American Academy of Ophthalmology annual meeting: Subspecialty Day - Retina; 2006 Nov 11-14; Las Vegas (NV)
67. Michels S, Hansmann F, Geitzenauer W, et al. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006; 47: 371-6
68. Jabs DA, Bressler NM, Gilson MM, et al. Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration: results from a randomized clinical trial [abstract]. Retina Society/Club Jules Gonin Annual Meeting; 2006 Oct 15-20; Cape Town
69. Brown JC, Solomon SD, Bressler SB, et al. Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol 2004; 122: 330-5
70. King RC. Exudative diabetic retinopathy. Br J Ophthalmol 1963; 47: 666-72
71. Sigurdsson R, Begg I. Organized macular plaques in exudative diabetic maculopathy. Br J Ophthalmol 1980; 64: 392-7
72. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
73. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XV. The long-term incidence of macular edema. Ophthalmology 1995; 102: 7-16
74. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703-13
75. Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45: 910-8
76. Lewis H, Schachat AP, Haimann MH, et al. Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 1990; 97: 503-11
77. Writing Committee for the Diabetic Retinopathy Clinical Research Network; Fong DS, Strauber SF, Aiello LP, et al. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007 Apr; 125 (4): 469-80
78. Conti SM, Kertes PJ. The use of intravitreal corticosteroids, evidence-based and otherwise. Curr Opin Ophthalmol 2006; 17: 235-44
79. Wang YS, Friedrichs U, Eichler W, et al. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 2002; 240: 42-8
80. Edelmamn JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005; 80: 249-58
81. Spandau UH, Derse M, Schmitz-Valckenberg P, et al. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol 2005; 89: 999-1003
82. A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema [online]. Available from URL: http:// public.drcr.net/DRCRnetstudies/studies/ProtocolB_steroid/ProtBInfo.html [Accessed 2007 Jun 30]
83. Diabetic Retinopathy Clinical Research Network, Chew E, Strauber S, et al. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology 2007 Jun; 114 (6): 1190-6
84. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7
85. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-50
86. Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006; 113: 1706-12
87. A phase 2 evaluation of anti-VEGF therapy for diabetic macular edema: bevacizumab (Avastin) [online]. Available from URL: http://public.drcr.net/ DRCRnetstudies/studies/ProtocolH_antievgf/ProtHInfo.html [Accessed 2007 Jun 30]
88. Intravitreal ranibizumab or triamcinolone acetonide in combination with laser photocoagulation for diabetic macular edema [online]. Available from URL: http://public.drcr.net/DRCRnetstudies/studies/ProtocolI_lrtdme/ProtIInfo.html [Accessed 2007 Jun 30]
89. Bullock WH, Magnuson SR, Choi S, et al. Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications. Curr Top Med Chem 2002; 2: 915-38
90. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy; initial results of the protein kinase C β inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005; 54: 2188-97
91. Poulsen J. The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmond's disease. Diabetes 1953; 2: 7-12
92. Smith LE, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997; 276: 1706-9
93. Grant MB, Mames RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000; 23: 504-9
94. Kaiser PK, Rieman CD, Sears JE, et al. Macular traction detachment and diabetic macular edema associated with posterior hyaloid traction. Am J Ophthalmol 2001; 131: 44-9
95. Massin P, Graham D, Erginay A, et al. Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol 2003; 135: 169-77
96. Evaluation of vitrectomy for diabetic macular edema [online]. Available from URL: http://public.drcr.net/DRCRnetstudies/studies/ProtocolD_vitrectomy/ ProtDInfo.html [Accessed 2007 Jun 30]
97. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 2006; 103: 3896-901
98. Tao W, Wen R, Goddard MB, et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 2002; 43: 3292-8
99. Francis PJ, Stout JT. Gene therapy and control of angiogenesis. Ophthalmol Clin North Am 2003; 16: 575-82
100. Edwards AO, Ritter III R, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308: 421-4